Insights Into Heart-Tumor Interactions in Heart Failure

Circulation Research, Год журнала: 2025, Номер 136(11), С. 1262 - 1285

Опубликована: Май 22, 2025

Heart failure (HF) often coexists with cancer. Beyond the known cardiotoxicity of some cancer treatments, HF itself has been associated increased incidence. The 2 conditions share common risk factors, mechanisms, and interactions that can worsen patient outcomes. bidirectional relationship between presents a complex interplay factors are not fully understood. Recent preclinical evidence suggests may promote tumor growth via release protumorigenic from injured heart, revealing as potentially condition. Our review discusses biological crosstalk cancer, emphasizing impact on growth, inflammation, modulating immune system central mechanisms. We further explore clinical implications this connection propose future research directions. Understanding mechanistic overlap could lead to new biomarkers therapies, addressing growing prevalence both enhancing approaches diagnosis, prevention, treatment.

Язык: Английский

---

Cardiovascular Considerations During Cancer Therapy

JACC CardioOncology, Год журнала: 2024, Номер 6(6), С. 815 - 834

Опубликована: Ноя. 5, 2024

Язык: Английский

---

Cardio-Oncology and Our Community

JACC CardioOncology, Год журнала: 2025, Номер 7(1), С. 82 - 82

Опубликована: Янв. 1, 2025

Язык: Английский

---

Clinical, Analytical, and Echocardiographic Associations of Impaired Cardiorespiratory Fitness After Anthracycline Chemotherapy in Breast Cancer: EPIC Fitness Study

Echocardiography, Год журнала: 2025, Номер 42(1)

Опубликована: Янв. 1, 2025

ABSTRACT Purpose This study explores the effects of anthracycline chemotherapy (AC) on breast cancer patients, focusing changes in body composition, advanced echocardiographic parameters at rest and during exercise, biomarkers; subsequently assesses whether these are associated with impaired cardiorespiratory fitness (CRF). Methods In this prospective study, we evaluated women early‐stage undergoing AC three visits: before AC, 1 month after, 6 months post‐AC. Results The included 32 cancer, functional disability increasing from 9.0% pre‐AC to 43.8% 53.1% At month, patients exhibited higher rates therapy‐related cardiac dysfunction (CTRCD) (85.7% vs. 55.5%) and, showed lower left ventricular ejection fraction (LVEF), reduced contractile reserve stroke volume (SV); along elevated IL‐6, PlGF, MPO levels. By months, maintained CTRCD (35.3% 0%), SV output (CO), global longitudinal strain (GLS), decreased work index (GWI). During they had SV; additionally, levels increased visceral fat. our multivariable model: age, fat, resting GWI, exercise LVEF, CO were independently VO 2 peak. Conclusion Significant persistent CRF reductions common While LVEF GLS not linked peak, MWI were, potentially identifying long‐term heart failure risk who would benefit cardioprotective strategies like cardio‐oncology rehabilitation. It is important recognize that multifactorial, as demonstrated by age fat being impact non‐cardiac factors should be better studied. Our findings highlight need for further research definition, suggesting CPET echocardiography could enhance stratification.

Язык: Английский

---

Association Between Advanced TNM Stages and Increased Risk of Cardiac Dysfunction in Patients with LVEF < 50%

Medicina, Год журнала: 2025, Номер 61(2), С. 301 - 301

Опубликована: Фев. 10, 2025

Background and Objectives: Cardio-oncology addresses the growing concern of cardiovascular complications arising from cancer therapies. Although treatments have greatly enhanced survival outcomes, they frequently carry substantial risks to health. This research examines toxicity associated with HER2-targeted therapies, focusing on interconnection between tumor characteristics, including histopathological profiles TNM classification, development complications. The objective is identify key correlations that inform better prevention management strategies for cardiotoxicity in oncology patients. Materials Methods: retrospective study analyzed patients undergoing cytostatic treatments, particularly anthracyclines, radiotherapy, Cardiac function was monitored using echocardiographic assessments, global longitudinal strain left ventricular ejection fraction (LVEF). Patients were stratified based staging findings evaluate treatment regimens outcomes. Results: analysis revealed a significant association advanced stages reduced LVEF, stage T4 showing highest prevalence cardiac dysfunction. Cytostatic such as anthracyclines identified contributors cardiotoxicity, advanced-stage These emphasize importance regular monitoring detect early signs pre-existing risk factors demonstrated higher Conclusions: highlights need personalized approaches tailored cardioprotective improve outcomes enhance quality life Future studies should prioritize developing improved reduce linked contemporary treatments.

Язык: Английский

---

Capecitabine-induced Cardiotoxicity Complicated with Acute Coronary Syndrome and Acute Heart Failure: A Case Report and Review of Scientific Data

Cardiologia Croatica, Год журнала: 2025, Номер 20(3-4), С. 76 - 83

Опубликована: Фев. 28, 2025

Язык: Английский

---

Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT guide): a phase 1 randomized clinical trial

Breast Cancer Research and Treatment, Год журнала: 2025, Номер unknown

Опубликована: Апрель 2, 2025

Breast cancer treatment results in increased cardiotoxicity risk; a risk-guided approach to cardioprotection has not been fully tested. This single-center, randomized Phase I trial enrolled patients with Stage I-III breast who planned receive anthracycline and/or trastuzumab therapy. An internally validated risk score classified participants as low or elevated risk. Elevated were open-label carvedilol usual care for 12 months, beginning at therapy initiation. Study visits occurred baseline, 3, 6, 9, 12, and 24 months. Primary outcomes included feasibility, safety, tolerability. Exploratory echocardiography, biologic, patient-reported measures. Of the 166 eligible approached, 68 (41%) agreed participate ultimately enrolled. Among these (median age 52, 35% Black), 49 19 Within group, 13 6 care. For those carvedilol, median maximum dose was 6.25 mg twice daily, 93% adherence. Adverse events of interest (grade 3 + bradycardia, hypotension, fatigue) 9% 13% care, 4% groups. One (1.5%) participant experienced cardiac dysfunction. There no substantial differences secondary across The withdrawal rate 7%. 1 demonstrates that strategy can be applied active cancer. However, additional strategies are necessary optimize design execution non-treatment intervention trials NCT04023110.

Язык: Английский

---

Bridging Cancer and Cardiovascular Health: A Comprehensive Review of Cardiotoxicity in Modern Oncology

Heart and Mind, Год журнала: 2025, Номер 9(2), С. 115 - 135

Опубликована: Март 1, 2025

Abstract As survival rates for cancer patients improve due to advancements in treatment modalities, there is an increasing prevalence of cardiovascular complications, necessitating a comprehensive understanding this intersection. This review aims elucidate the intricate relationship between and disease, highlighting growing concern toxicity associated with therapies. It explores various treatments, including chemotherapy, targeted therapies, radiation, their risks, such as heart failure ischemic disease. In addition, it discusses importance proactive risk assessments ongoing monitoring mitigate adverse outcomes. Strategies prevention management, lifestyle modifications pharmacologic interventions, are also examined support health survivors. Unlike previous reviews, work integrates insights from multidisciplinary collaborations, emphasizing underexplored mechanisms role innovative tools. highlights emerging therapeutic strategies tailored these providing forward-looking perspective critical area research. The need collaborative method that includes oncologists, cardiologists, primary care providers emphasized ensure integrated addresses both health. serves resource healthcare professionals seeking long-term outcomes survivors by recognizing managing risks.

Язык: Английский

---

Risk Factors and Prevention of Cancer and CVDs: A Chicken and Egg Situation

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(9), С. 3083 - 3083

Опубликована: Апрель 29, 2025

Cardiovascular diseases and cancer are the two primary causes of mortality worldwide. Although traditionally regarded as distinct pathologies, they share numerous pathophysiological mechanisms risk factors, including chronic inflammation, insulin resistance, obesity, metabolic dysregulation. Notably, several cancers have been identified closely linked to cardiovascular diseases, lung, breast, prostate, colorectal cancers, well hematological malignancies, such leukemia lymphoma. Additionally, renal pancreatic exhibit a significant association with complications, partly due shared factors cardiotoxic effects therapies. Addressing overlapping through lifestyle modifications-such regular physical activity, balanced diet, cessation smoking alcohol-has proven effective in reducing both CV oncological morbidity mortality. Furthermore, even patients established cancer, structured interventions targeting nutritional optimization, associated improved outcomes. Beyond modifications, pharmacological strategies play crucial role prevention diseases. Several medications, statins, aspirin, beta-blockers, metformin, pleiotropic that extend beyond their indications, demonstrating potential anti-neoplastic properties preclinical observational studies. Recently, novel therapeutic agents garnered attention for possible cardioprotective benefits. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) sodium-glucose cotransporter-2 inhibitors (SGLT2is), initially developed managing type 2 diabetes, shown protective effects, alongside emerging evidence modulating cancer-related pathways. Inclisiran, small interfering RNA PCSK9, effectively lowers LDL cholesterol may contribute risk, implications tumor biology. sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has revolutionized heart failure management by improving hemodynamic parameters exerting anti-inflammatory broader disease prevention. Given intricate interplay between CVD further research is essential clarify exact linking these conditions assessing therapies This review aims examine consider interventions, emphasize epidemiological mechanistic insights into intersection health.

Язык: Английский

---

Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology

Pharmaceuticals, Год журнала: 2025, Номер 18(5), С. 681 - 681

Опубликована: Май 3, 2025

Cancer remains the second leading cause of death worldwide. Doxorubicin (DOX) is a cornerstone hematologic malignancy treatment, but it limited by its dose-dependent cardiotoxicity, to systolic and diastolic cardiac dysfunction and, ultimately, dilated hypokinetic cardiomyopathy. Cardio-oncology has emerged as subspecialty addressing cardiovascular complications in cancer patients, highlighting preventive therapeutic strategies reduce therapy-related (CTRCD). Current approaches, including beta-blockers, renin–angiotensin system (RAS) inhibitors, statins, offer partial cardioprotection. Sodium-glucose cotransporter-2 (SGLT2) initially developed for type 2 diabetes mellitus (T2DM), demonstrate pleiotropic cardioprotective effects beyond glycemic control, reduced oxidative stress, inflammation, myocardial remodeling. This review explores interplay between anthracycline therapy, particularly DOX, cardiotoxicity while evaluating SGLT2 inhibitors novel agents cardio-oncology. Preclinical studies suggest attenuate CTRCD preserving mitochondrial function inhibiting apoptosis, clinical trials highlight their efficacy reducing heart failure (HF) hospitalizations (CV) mortality. Integrating into cardio-oncology protocols could revolutionize management CTRCD, enhancing patient outcomes oncology care. Considering emerging evidence, may provide significant benefits patients undergoing those with elevated risk profiles. We recommend that future prospective, large-scale further evaluate safety these therapy optimize individualized treatment strategies.

Язык: Английский

---